230 filings
Page 2 of 12
8-K
2mod73brlxdrf5shiji
27 May 22
Regulation FD Disclosure
8:44am
8-K
s846rwvqmy
12 Jan 22
Hepion Pharmaceuticals Announces Death of Director, Thomas Adams
10:08am
8-K
49wf4y
10 Jan 22
Regulation FD Disclosure
6:02am
8-K
iqxvm6 m15olz0gj
6 Jan 22
Hepion Pharmaceuticals Announces USAN Selection of “Rencofilstat” as Nonproprietary Name for CRV431
5:18pm
8-K
jt5s77dnogsbwif
21 Dec 21
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 in the Treatment of Liver Cancer
8:25am
8-K
lhvkwoy
30 Nov 21
Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431 for the Treatment of NASH
8:10am
8-K
x2a81mb 8cez25t1
16 Nov 21
Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of CRV431 in a Nonclinical Liver Cancer Study
8:53am
8-K
i54sknsk5 6s
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
exkay phovft2salpn
8 Oct 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
24sb1oqey82qw7
7 Oct 21
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
4:24pm
8-K
5ulbmc2t4p 8a
30 Sep 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES October 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
5:22pm
8-K
uvc258dqnpmrw kcmi0l
29 Sep 21
Other Events
9:22am
8-K
0xfsei1w
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
z3251ssg ghlnj1aw6as
23 Aug 21
Amendments to Articles of Incorporation or Bylaws
9:19am
8-K
woz2jgpn2d6x8dzgmn
26 Jul 21
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
12:00am
8-K
f7pk1m5zgms7x
13 Jul 21
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
10:38am
8-K
opucj rbkl2ek
25 Jun 21
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
4:46pm
8-K
0akz1yzpki g6x0h8
9 Jun 21
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
9:06am
8-K
q6axtwe4p5 1pdk2er
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
mke2bus1zruert1ik83
29 Apr 21
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
10:07am